Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.
The study highlights microbial natural products as abundant sources of new drug leads. The researchers’ discovery process involves prioritizing the microbes from the TSRI strain collection and focusing on the ones that are genetically predisposed to produce specific families of natural products. The scientists say this process saves time and resources in comparison to the traditional approaches used to identify these rare molecules.
The study, led by TSRI Professor Ben Shen, was published today in the journal mBio.
Shen and his colleagues uncovered a new family of enediyne natural products, called tiancimycins, (TNMs) which kill selected cancer cells more rapidly and completely in comparison to toxic molecules used in FDA-approved antibody-drug conjugates (ADCs)— monoclonal antibodies attached to cytotoxic drugs that target only cancer cells.
The scientists also discovered several new producers of C-1027, an antitumor antibiotic currently in clinical development, which can produce C-1027 at much higher levels.
It has been more than a decade since Shen first reported on the C-1027 enediyne biosynthetic machinery, and he speculated then that the knowledge obtained from studying biosynthesis of C-1027, and other enediynes, could be used for the discovery of novel enediyne natural products.
“The enediynes represent one of the most fascinating families of natural products for their extraordinary biological activities,” Shen said. “By surveying 3,400 strains from the TSRI collection, we were able to identify 81 strains that harbor genes encoding enediynes. With what we know, we can predict novel structural insights that can be exploited to radically accelerate enediyne-based drug discovery and development.”
“The work described by the Shen group is an excellent example of what can be achieved by coupling state of the art genomic analyses of potential biosynthetic clusters and modern physicochemical techniques,” said David J. Newman, retired chief of the National Cancer Institute’s Natural Products Branch. “As a result of their work, the potential number of enediynes has significantly increased.”
Shen’s method of strain prioritization and genome mining means a far more efficient use of resources involved in the discovery process, targeting only those strains that look to produce the most important natural compounds.
“This study shows that the potential to rapidly discover new enediyne natural products from a large strain collection is within our reach,” said TSRI Research Associate Xiaohui Yan, one of four first authors of the study. “We also show the feasibility of manipulating tiancimycin biosynthesis in vivo, which means that sufficient quantities of these precious natural products can be reliably produced by microbial fermentation for drug development and eventual commercialization.”
Receive an email update when we add a new ANTI-CANCER DRUG article.
The Latest on: Anticancer drug
via Google News
The Latest on: Anticancer drug
- Drug combo could treat triple-negative breast canceron April 6, 2020 at 4:00 pm
The US Food and Drug Administration has already approved a number of MEK inhibitors ... within a substantial fraction of triple negative breast cancers and in a higher rate of cases that don’t respond ...
- Trump pushes unproven drug for virus; doctors waryon April 6, 2020 at 2:33 pm
President Donald Trump and his administration kept up their out-sized promotion Monday of an malaria drug not yet officially approved for fighting the new coronavirus, even though scientists say more ...
- Immunomedics News: IMMU Stock Rockets on Promising Breast Cancer Drugon April 6, 2020 at 12:10 pm
The study, referred to as ASCENT, began to test the drug’s treatment of triple-negative breast cancer (TNBC ... “Triple-negative breast cancer (TNBC) is a disease with extremely limited treatment ...
- White House pushes unproven drug for virus, but doctors waryon April 6, 2020 at 9:29 am
President Donald Trump and members of his administration are growing emphatic in promoting an anti-malaria drug not yet officially approved for fighting COVID-19, even though scientists say more ...
- Shilpa Medicare's subsidiary gets UK regulator nod for anti-cancer drugon April 5, 2020 at 10:35 pm
The subsidiary of Shilpa Medicare on April 6 has received approval from the UK health regulator for anti-cancer drug Imatinib. "The approval of Imatinib Oral Solution represents a major step forward ...
- Comparison of microtubules stabilized with the anticancer drugs cevipabulin and paclitaxelon April 5, 2020 at 9:15 pm
Stabilization of microtubules occurs by paclitaxel bound to the taxoid site and cevipabulin (and its derivative) bound to the taxoid site and/or vinca alkaloid domain of the β-tubulin in tubulin ...
- Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activityon April 3, 2020 at 2:15 am
The specificity of the two different Pt-species towards bone tissue relative to other soft tissues is depicted in Fig. 1C as the percentage of injected dose per gram of tissue (%ID/g). Higher uptake ...
- Chemotherapy Drugs Market Size, Growth , Leading Players and Forecast To 2023on April 3, 2020 at 1:22 am
Executive Summary A comprehensive research report created through extensive primary research (inputs from industry ...
- Tailoring an anti-cancer drug for optimal tumor cell killingon April 2, 2020 at 11:00 am
In a study published this week in Science, Université de Montreal researchers report key structural and biochemical differences among a class of anti-cancer drugs known as PARP inhibitors. These ...
via Bing News